Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Century Therapeutics (IPSC) FCF Margin (2022 - 2025)

Century Therapeutics has reported FCF Margin over the past 4 years, most recently at 32.15% for Q1 2025.

  • Quarterly FCF Margin rose 356867.0% to 32.15% in Q1 2025 from the year-ago period, while the trailing twelve-month figure was 95.95% through Dec 2025, up 158749.0% year-over-year, with the annual reading at 95.95% for FY2025, 157788.0% up from the prior year.
  • FCF Margin was 32.15% for Q1 2025 at Century Therapeutics, up from 580.47% in the prior quarter.
  • Over five years, FCF Margin peaked at 7840.93% in Q1 2022 and troughed at 28046.46% in Q2 2023.
  • The 4-year median for FCF Margin is 3579.38% (2024), against an average of 4943.69%.
  • Year-over-year, FCF Margin crashed -2646530bps in 2023 and then soared 2446709bps in 2024.
  • A 4-year view of FCF Margin shows it stood at 5599.81% in 2022, then crashed by -81bps to 10152.99% in 2023, then surged by 94bps to 580.47% in 2024, then skyrocketed by 94bps to 32.15% in 2025.
  • Per Business Quant, the three most recent readings for IPSC's FCF Margin are 32.15% (Q1 2025), 580.47% (Q4 2024), and 3581.8% (Q3 2024).